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Genetic defects such as copy number variations (CNVs) in non-coding regions containing conserved 
non-coding elements (CNEs) outside the transcription unit of their target gene, can underlie genetic 
disease. An example of this is the short stature homeobox (SHOX) gene, regulated by seven CNEs 
located downstream and upstream of SHOX, with proven enhancer capacity in chicken limbs. CNVs of 
the downstream CNEs have been reported in many idiopathic short stature (ISS) cases, however, only 
recently have a few CNVs of the upstream enhancers been identified. Here, we set out to provide 
insight into: (i) the cis-regulatory role of these upstream CNEs in human cells, (ii) the prevalence of 
upstream CNVs in ISS, and (iii) the chromatin architecture of the SHOX cis-regulatory landscape in 
chicken and human cells. Firstly, luciferase assays in human U2OS cells, and 4C-seq both in chicken 
limb buds and human U2OS cells, demonstrated cis-regulatory enhancer capacities of the upstream 
CNEs. Secondly, CNVs of these upstream CNEs were found in three of 501 ISS patients. Finally, our 
4C-seq interaction map of the SHOX region reveals a cis-regulatory domain spanning more than 1 Mb 
and harbouring putative new cis-regulatory elements.
The short stature homeobox-containing gene (SHOX; MIM *312865) is located in the pseudoautosomal 
region (PAR1) on the short arms of the X- and Y-chromosomes1. SHOX is a member of the paired-like 
homeobox-containing protein family of transcription factors, and plays a crucial role in bone develop-
ment and growth1–3. A strict regulation of its spatiotemporal expression is therefore of utmost impor-
tance. As for most developmental genes, the minimal promoter region of SHOX is not sufficient but 
requires the assistance of cis-regulatory elements such as enhancers4. To date, seven evolutionarily con-
served non-coding elements (abbreviated as CNEs, ECRs or ECS) located downstream (CNE4, CNE5, 
ECR1 and ECS4/CNE9) and upstream (CNE-5, CNE-3 and CNE-2) of SHOX, have been shown to act 
as enhancers5–8. As SHOX does not have an orthologue in rodents but is highly conserved in chicken3, 
and as Shox expression was shown in chicken limb buds at developmental stage HH266, limb buds of 
chicken embryos have been used to confirm the enhancer potential of all CNEs, except for ECR16,7. 
In addition, chromosome conformation capture (3C) in chicken embryo limbs demonstrated that the 
downstream ECR1 and CNE9 interact with the Shox promoter8. Interestingly, the regulatory capacity of 
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CNE4, CNE5 and CNE9 was also investigated in whole zebrafish embryos resulting in the identifica-
tion of additional tissues under the regulatory control of these CNEs and the identification of smaller, 
more deeply conserved sub-sequences within these CNEs9. Cotney et al. recently performed H3K27ac 
ChIP-seq profiling in human embryonic limb buds from day 33 (E33) through to E4710. This revealed 
a genome-wide distribution of the active enhancer-associated histone marks H3K27ac in human limbs 
of different developmental stages. Despite all this data, functional studies specifically investigating the 
cis-regulatory activity of the upstream CNEs in relevant human systems are lacking as only the enhancer 
potential of the four downstream CNEs was substantiated in human U2OS osteosarcoma cells.
Heterozygous defects of SHOX or its enhancers explain ~60–80% of cases with Leri-Weill dyschon-
drosteosis (LWD, MIM 127300) and ~2–5% of cases with idiopathic short stature (ISS, MIM 300582), 
which is defined as a height below − 2 standard deviations (SDS) in the absence of known causes11. 
Molecular defects leading to both phenotypes include intragenic SHOX mutations, complete or par-
tial SHOX deletions and duplications, and deletions and duplications of the downstream enhancer 
region1,12–21. Interestingly, only one deletion and duplication of the upstream enhancer region, have been 
described in ISS patients21,22.
Here, our aim was to provide insight into: (i) the cis-regulatory role of these upstream CNEs in relevant 
human cells, (ii) the prevalence of copy number variations (CNVs) of upstream CNEs in ISS, and (iii) the 
chromatin architecture of the SHOX cis-regulatory landscape in chicken and human cells. Luciferase assays of 
the upstream CNEs revealed enhancer activity in human U2OS cells. In addition, these CNEs overlap with 
H3K27ac ChIP-seq marks previously generated in human embryonic limb buds. Furthermore, 4C-seq in 
chicken embryo limb buds and in U2OS cells uncovered interactions of the upstream CNEs with the Shox 
promoter. CNVs of these upstream CNEs were found in only three of 501 patients with unexplained ISS.
Results
Luciferase assays of upstream CNEs in human U2OS osteosarcoma cells. In ovo enhancer 
assays in chicken limb buds previously demonstrated that the upstream CNEs possess enhancer activity7. 
However, enhancer assays in relevant human cells have not yet been performed. Hence, luciferase assays 
of the upstream enhancers, CNE-5, CNE-3 and CNE-2, were carried out in human U2OS cells. For this 
purpose, the CNEs were cloned upstream of the SHOX promoter in the pGL3SHOXprom vector8, mim-
icking their chromosomal localization. The clones were co-transfected with a Renilla luciferase control 
vector into U2OS cells. The four downstream SHOX enhancer regions CNE4, CNE5, ECR1 and ECS4/
CNE9 were used as positive controls whilst the pGL3SHOXprom vector with no enhancer sequence was 
Figure 1. Enhancer activity of three upstream CNEs demonstrated by in vitro luciferase assays in human 
U2OS cells. Luciferase reporter activity of U2OS cells transfected with the pGL3SHOXprom enhancer 
reporter plasmids and the Renilla luciferase control plasmid. The pGL3SHOXprom without any enhancer 
inserted was used as an empty vector, to normalize luciferase activity. Fold increase values were obtained by 
normalizing the relative luciferase units of each sample, first, with respect to the Renilla luciferase activity, 
and second, to that transfected with the empty reporter plasmid. All values represent the mean and standard 
deviation of two biological replicates with each sample assayed in triplicate. ECS5, localized outside of the 
deleted region and which has previously been shown not to have enhancer activity, was utilized as a negative 
control5. The downstream SHOX enhancer regions CNE4, CNE5, ECR1 and CNE9/ECS4 were utilized 
as positive controls6,8. Increased luciferase activity was observed for all three upstream SHOX enhancer 
constructs, CNE-5, CNE-3 and CNE-2 constructs and the positive controls.
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used as the negative control. Increased luciferase activity was observed for all three upstream CNEs and 
positive controls (Fig. 1). The three upstream CNEs were also cloned downstream of the luciferase gene, 
to test out their localization dependency. All three showed enhancer activity (Fig. 1), demonstrating that 
the upstream CNEs act as enhancers in a localization independent manner in human U20S cells.
Exploration of the SHOX region in H3K27ac ChIP-seq marks in human embryonic limb buds10 
showed the presence of active marks in all three upstream CNEs (CNE-5, CNE-3 and CNE-2), substan-
tiating their enhancer activity in the human developing limb (Fig. 2).
Copy number profiling of upstream CNEs in cohort with unexplained ISS. CNV analysis of 
upstream CNEs. The study cohort consisted of 501 ISS patients. Deletions and duplications of SHOX and 
the downstream enhancer region were excluded prior to this study18, and intragenic mutations of SHOX 
were excluded in 56 of the 501 patients by Sanger sequencing of the coding regions. In the remaining 
445 patients, coding mutations were excluded by a customized targeted amplicon-based next-generation 
sequencing approach23.
Overall, 501 patients with unexplained ISS underwent CNV analysis of the upstream enhancer region 
(CNE-5, CNE-3, CNE-2). A CNV of at least two of the upstream enhancers (two deletions, one dupli-
cation) was detected in three unrelated index cases (patients A, B and C) (Fig.  3). These CNVs were 
confirmed and delineated using customized high-resolution arrayCGH (Supplementary Fig. S1). An 
overview of these novel and previously reported upstream CNVs21,22 is given in Fig.  4. A summary of 
the sex, age, anthropometric and clinical details of the probands with these upstream CNVs and their 
family members is shown in Table 1.
In patient A, we found a deletion of ~91 kb encompassing CNE-3 and CNE-2 (Fig.  3). Patient A is a 
9-year-old Belgian girl referred for ISS (115.8 cm, − 2.3 height standard deviation score, SDS), with a reduced 
arm span:height ratio which is indicative of shortening of upper limbs and suggestive of LWD. Her parents’ 
heights were both within normal limits. The deletion was shown to be paternal (Supplementary Fig. S2).
In patient B, a deletion of ~139 kb was observed containing CNE-5 and CNE-3 (Fig. 3). Patient B is a 
13-year-old boy of Roma origin referred for ISS (130.5 cm, − 2.5 SDS). His father’s height is 170 cm (1.03 
SDS) and his mother’s height is 152 cm (− 1.96 SDS). Paternal inheritance of the deletion was excluded 
but no maternal material was available to substantiate a maternal origin (Supplementary Fig. S2).
A duplication of ~256 kb containing all three upstream CNEs was identified in patient C (Fig.  3). 
Patient C is a 17-year-old Belgian girl with disproportionate short stature (153 cm, − 2.3 SDS). Her 
father´s height is 163 cm (− 2.6 SDS) and her mother’s height is 156 cm (− 1.8 SDS). The duplication was 
shown to be paternal (Supplementary Fig. S2).
Structural variations of the SHOX region in open source and local databases. No upstream CNVs were 
identified in a control population of 340 healthy individuals with heights within the normal range21,22. 
To further evaluate the prevalence and associated phenotypic effects of the upstream CNVs, we searched 
for deletions and duplications of these regions in the Database of Genomic Variants (DGV)24, Database 
Figure 2. H3K27ac distribution of the SHOX locus in human embryonic limbs from embryonic day 33 
(E33) through E47. Overview of the human SHOX locus (chrX:350,000–628,000; UCSC, Human Genome 
Browser, hg19), showing the distribution of enhancer-associated H3K27ac histone marks at different human 
embryonic limb bud stages, produced by Cotney et al. (2013) and retrieved from GEO dataset GSE42413. 
Four embryonic stages are represented: E33, E41, E44 and E47. Upstream enhancers CNE-5, CNE-3 
and CNE-2 are highlighted with red bars. The two SHOX isoforms are represented in blue at the top. A 
conservation track is represented at the bottom.
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of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources (Decipher)25, and our 
local arrayCGH database. Four duplications of the upstream region were present in DGV26–28 while 19 
duplications and one deletion were reported in Decipher. However, short stature was only listed as part 
of the phenotypic spectrum for one of the duplications in Decipher. This duplication was predicted to 
be benign as the patient had three other CNVs, one of which was classified as probably pathogenic. 
Similarly, the majority of the Decipher listed CNVs encompassing the upstream enhancers are classified 
as likely benign and occur in combination with other CNVs25 (Supplementary Table S3).
In our local array CGH database, containing genomic profiles from over 3000 patients, one deletion 
and two duplications of the upstream enhancers were found in patients with syndromic phenotypes. As 
two of these patients display short stature in combination with a variety of symptoms, the short stature 
may be part of a syndrome and caused by a different genetic defect (Supplementary Table S3).
Chromatin interaction map (4C-seq) in chicken limb buds and in human U2OS cells. Several 
genomic alterations associated with SHOX-deficient phenotypes have been found within regulatory 
domains both upstream and downstream of the SHOX coding region15,16,20–22. Subsequent functional 
studies identified seven CNEs with enhancer properties in these regions and 3C analysis showed the inter-
action of downstream elements with the Shox promoter5–8, suggesting a complex regulation of SHOX. To 
further map the cis-regulatory landscape of Shox, we used 4C-seq, a chromosome conformation capture 
technique that has been used to identify cis-regulatory elements associated with Hox genes29–31. Using the 
Shox promoter as an anchor point, 4C-seq in chicken limb buds revealed widespread contacts between 
Shox and multiple upstream and downstream regions. The region extended almost 800 kb in the chicken 
genome, a region syntenic with approximately 1 Mb of human genomic DNA (Fig. 5A). All three known 
upstream enhancers (CNE-5, CNE-3 and CNE-2) contacted with the Shox promoter. Similar results 
were generated using 4C-seq in human U2OS cells (Fig. 5B). Interestingly, integration of the previously 
generated H3K27ac ChIP-seq marks in the SHOX locus with the 4C-seq peaks revealed numerous other 
Figure 3. Copy number profiling of upstream CNEs (CNE-5, CNE-3 and CNE-2) revealing two 
upstream deletions and one duplication. Each panel shows the results of the CNV analysis using qPCR. 
The qPCR-derived copy number results are presented as relative quantities in a bar chart. Normal copy 
numbers are represented in grey, deletions are shown in red and duplications in blue. Error bars are added 
to allow interpretation of the assay’s precision.
Figure 4. Overview of all reported upstream CNVs in the SHOX region. Overview of the SHOX region 
(hg19: chrX:151,000-628,000; UCSC, Human Genome Browser, hg19) with custom tracks showing the 
deletions (red bars) and duplications (blue bars) identified in this and previous studies21,22. A custom track 
representing the upstream enhancers (CNE-5, CNE-3 and CNE-2) is included, the RefSeq Genes track is 
shown at the top.
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active regions, upstream and downstream of the SHOX transcription unit (Fig. 5C). These findings sug-
gest a complex regulation of SHOX expression by multiple cis-regulatory elements located upstream and 
downstream of the coding region within a large genomic region extending beyond 1 Mb (approximate 
boundaries chrX:284,600-1,355,600, hg19).
Discussion
CNVs of cis-regulatory elements of strict spatiotemporally regulated transcription factor genes can often 
underlie human developmental disease, as is the case for SHOX, which is regulated by at least seven 
enhancers located downstream and upstream of SHOX5–8. Indeed, enhancer activity of the upstream 
CNEs (CNE-5, CNE-3, CNE-2) has been previously demonstrated by in ovo enhancer assays in chicken 
limb buds, however, specific functional data in relevant human cells are lacking. We therefore performed 
luciferase assays in human U2OS cells, showing increased luciferase activity for all three upstream CNEs 
in a localization-independent manner, confirming their enhancer activity in human cells. In addition, the 
upstream CNEs overlap with previously identified active enhancer-associated histone H3K27ac marks in 
human limbs of different developmental stages10. Cis-regulatory elements can only fulfil their function 
if the chromatin is in an open euchromatic conformation and if they can communicate with the pro-
moter of a target gene4. The most favoured model to explain such communication is the looping model 
where transcription factors bound at the enhancer make direct contact with the promoter and/or with 
factors bound at the promoter, while the intervening DNA loops out32. This model forms the basis for 
the 3C/4C methods, which allow the identification of interactions between genomic fragments33. To test 
the interactions of the upstream enhancers, we performed 4C-seq in limb buds of chicken embryos and 
in human U2OS cells. Both experiments demonstrated interactions for all three upstream CNEs and the 
Shox promoter, emphasizing their cis-regulatory role in both chicken and human cells.
SHOX deficiency can result from a variety of molecular defects including intragenic SHOX mutations, 
complete and partial CNVs of SHOX, and CNVs of its enhancers located in the downstream PAR1 
region1,12–21. The first CNVs of the upstream enhancer, a deletion and a duplication, were only recently 
identified in ISS patients21,22. As the upstream region has only been included relatively recently in the 
most frequently used diagnostic tool for CNV analysis of SHOX and the PAR1 region (i.e. multiplex 
ligation-dependent probe amplification, MLPA), CNVs of the upstream enhancers may have been missed 
and therefore their contribution to the pathogenesis of SHOX-deficient phenotypes might have been 
underestimated. Here, CNV analysis of the upstream CNEs in 501 cases with unexplained ISS revealed 
two upstream enhancer deletions and one duplication. Thus, the frequency of upstream CNVs in our 
ISS cohort is only ~0.6% while an even lower frequency was reported by Benito-Sanz et al.22. These low 
numbers are in contrast with the high frequencies observed for downstream CNVs. This might have sev-
eral explanations: (i) Differences in the genomic content between the upstream and downstream region. 
Indeed, Durand et al. showed that the overall content of interspersed repeats of the downstream region 
is considerably higher than that of the upstream region thus increasing the probability of deletions and 
duplications7. (ii) Lack of screening studies of the upstream CNEs in large ISS cohorts as only this and 
the one reported by Benito-Sanz et al.22 have been undertaken to date. (iii) Smaller phenotypic effects 
of CNVs of upstream CNEs compared to those of downstream CNVs, which could be due to different 
spatiotemporal regulation, may lead to milder phenotypes that are not necessarily ascertained at genetic 
and endocrinology clinics22. In addition this could explain incomplete penetrance, as assumed for the 
upstream CNV detected in family A and for the previously reported upstream duplication21. Interestingly, 
incomplete penetrance was also observed in several families with the recurrent ~47.5 kb downstream 
deletion8, suggesting that CNVs of the upstream or downstream CNEs can act as rare functional variants 
that require (an) additional risk factor(s) to express their phenotypes. This is also supported by the rel-
atively high number of CNVs encompassing one or more upstream CNEs found in DGV and Decipher.
Patient CNV Age Ethnicity Gender
Anthropometric 
measurements (SDS) Birth details
Parental anthropometric 
measurements (SDS) Other clinical characteristics
A
~91 kb (arr[hg19] 
Xp22.33(426,377–
517,515)x1 pat)
9 yrs Caucasian F 115.8 cm (− 2.3 SDS)
Born at full term 
with a birth weight 
of 3.08 kg and birth 
length of 50 cm
Father: 182 cm (0.55 SDS) 
Mother: 163 cm (− 0.14 SDS)
X-rays of the wrists and lower 
arms were normal as were 
thyroid test and IGF-I levels. 
Arm span:height ratio was 0.95.
B
~139 kb (arr[hg19] 
Xp22.33(345,956–
485,020)x1)
13 yrs Roma M 130.5 cm (− 2.5 SDS) ND Father: 170 cm (1.03 SDS) Mother: 152 cm (–1.96 SDS) ND
C
~256 kb (arr[hg19] 
Xp22.33(283,986–
539,708)x3 pat)
17 yrs Caucasian F 153 cm (− 2.3 SDS)
Born at full term 
with a birth weight 
of 3.1 kg and birth 
length of 49 cm
Father: 163 cm (− 2.6 SDS) 
Mother: 156 cm (− 1.8 SDS)
X-rays of hand and wrist were 
normal. Shorter proximal 
extremities and clinodactyly of 
the fifth fingers.
Table 1.  Anthropometric and phenotypic characteristics of the probands with an upstream CNV and 
their parents. Abbreviations used (in alphabetical order): CNV: copy number variation; F: female; M: male; 
ND: not documented; SDS: height standard deviation score; yrs: years.
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Our data underscore that the clinical significance of upstream CNVs, especially duplications, is often 
ambiguous, hampering genetic counselling. The orientation and location of the duplicated segment, may 
cause overexpression of its target gene or interfere with the chromatin conformation, thereby impairing 
cis-regulation during development and causing disease34.
In ~60–80% of LWD and ~2–5% of ISS cases a SHOX-related genetic defect can be identified, leaving 
a large proportion of LWD and ISS cases molecularly unexplained. Besides the involvement of vari-
ants in other loci, genetic defects in novel, as yet unidentified cis-regulatory elements of SHOX may 
explain a proportion of these unexplained LWD and ISS cases. In order to delineate the cis-regulatory 
domain more precisely, we performed 4C-seq in different cells. Interestingly, the chromatin interaction 
maps delineate the cis-regulatory landscape of SHOX to a region that extends beyond 1 Mb in humans 
(approximate boundaries: chrX:284,600–1,355,600, hg19), which is larger than previously anticipated 
based on the genomic positions of the previously functionally studied CNEs (approximate boundaries: 
chrX:398,357–835,567, hg19). These data are consistent with the multiple enhancer-associated H3K27ac 
marks in human limbs distributed along the whole region and active at different developmental stages10. 
The boundaries proposed here appear to be larger than the topological domain (chrX:350,001–1,035,000) 
determined by Hi-C in GM12878 lymphoblastoid cells, (Supplementary Fig. S4)35. These differences can 
Figure 5. 4C-seq chromatin interaction map of the cis-regulatory region surrounding SHOX. (A) 4C-
seq data of the chicken Shox locus (chr1:133,215,000-134,400,000; UCSC, galGal3) showing that the Shox 
promoter (blue bar, viewpoint) interacts with 800 kb of adjacent genomic regions that likely contain Shox 
cis-regulatory regions, a region syntenic with about 1 Mb of human genomic DNA (shown in panel (B)). 
Red bar marks the position of the upstream CNEs. The 4C-seq data indicate that the Shox regulatory 
landscape extends both upstream and downstream of the currently known, functionally validated enhancers. 
(B) 4C-seq data of the human SHOX locus (chrX:215,733–1,561,244; UCSC, hg19) showing that the SHOX 
promoter (blue bar, viewpoint) interacts with the upstream enhancers (red bars). The RefSeq Genes are 
shown a the top and the conservation track is included at the bottom of panel (B). (C) Distribution of 
enhancer-associated H3K27ac histone marks at different human embryonic limb bud stages, produced by 
Cotney et al. (2013).
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be explained by the presence of several assembly gaps in the SHOX region for which consequently no 
Hi-C data can be generated. Taking this into account, the regulatory domains mapped both by Hi-C and 
4C-seq do have similar boundaries. This also illustrates that the spatial organisation of the genome in 
topological domains is stable across different cell types and is highly conserved throughout evolution36.
Integration of the 4C-seq interaction map generated here and H3K27ac histone marks will be instru-
mental for the identification of novel cis-regulatory elements. In this context, it is interesting to mention 
two recently reported deletions ~300 kb downstream of SHOX in LWD, not including any of the four 
known downstream enhancers37,38. These deletions harbour a high 4C-seq interaction peak and several 
H3K27ac marks possibly pointing to a novel SHOX enhancer (Supplementary Fig. S5). Further in vitro 
and in vivo assays are required however to substantiate this.
In conclusion, in vitro luciferase assays of upstream CNEs in human U2OS cells and active histone 
marks in human developing limbs support an enhancer role for the upstream CNEs in human cells. 
Chromosome conformation capture profiling (4C-seq) in embryonic chicken limb buds and human 
U2OS cells show cis-regulatory interactions of the upstream CNEs with the SHOX promoter. In addition, 
our study revealed a low frequency of upstream CNVs in a sizeable ISS cohort. Finally, the 4C-seq inter-
action and H3K27ac ChIP-seq profiles revealed that the cis-regulatory domain of SHOX extends beyond 
1 Mb surrounding SHOX. Thus, novel cis-regulatory elements may be located upstream and downstream 
of SHOX, of which variations might contribute to SHOX-deficient phenotypes.
Materials and Methods
Luciferase assays. The enhancer reporter constructs contained the upstream enhancers, CNE-5, 
CNE-3 and CNE-2 upstream of the human SHOX promoter (−432 to + 5 bp, NM_000451). 
The sequences including the upstream enhancers were amplified using the following primers: 
5′ - CAAACACGGAACAGCACACT -3′ and 5′ - CCTGGGACAGACACGACC -3′ for CNE-5, 
5′ - CGAGGTGGATCAAAGTG -3′ and 5′ - TGCTCTGCCATATCCTCAATC -3′ for CNE-3, and 5′ - 
ACATGACAGCCGGGCCTCTG -3′ and 5′ - GCGAGCCATAAAACAAGCTG -3′ for CNE-2, and 
cloned into the pGL3SHOXprom vector, upstream of the promoter (8), thus mimicking its chromosomal 
localization. The enhancers were also cloned downstream of the luciferase gene to test out localization 
dependency. The enzymes utilized were KpnI and NheI for cloning the enhancers upstream of the SHOX 
promoter and BamHI and SalI for cloning downstream of the luciferase gene. Luciferase assays were 
undertaken in human U2OS osteosarcoma cells, as previously reported8. The downstream SHOX enhanc-
ers, CNE4, CNE5, ECR1 and ECS4/CNE96,8 were also cloned and employed as positive controls while 
ECS55 and the empty pGL3SHOXprom vector (i.e. no enhancer) were used as negative controls. The data 
shown is the mean and standard deviations of three replicates of each transfection and two biological 
replicates, thus a total of six points for each enhancer.
Patient cohort. A total of 501 probands with ISS were referred to the Center for Medical Genetics in the 
Ghent University Hospital for genetic testing of the SHOX region. An informed consent was obtained from 
all subjects. Revisiting of clinical records was performed in cases in whom an upstream CNV was found. 
Whenever possible, clinical data included: sex, age, birth details, height standard deviation score (SDS) 
according to national standards, physical examination of extremities, X-rays of the lower arm and family 
histories including parental heights SDS (Table 1). The study was conducted in accordance with the tenets 
of Helsinki and was approved by the Ghent University Hospital Ethics Committee (approval 2004/094).
Pre-screening of SHOX and the neighbouring PAR1 region. Prior to this study, all cases were 
genotyped using our previously described PAR1 qPCR-based copy number analysis test18. As coding 
mutations of SHOX were excluded in only 56 of these cases by Sanger sequencing, the remainder of 
patients underwent in-house developed targeted next-generation sequencing (NGS) of the coding exons 
and intron-exon boundaries of SHOX (MiSeq, Illumina, San Diego, CA)23. Primers and PCR conditions 
used for the amplification of the coding regions of SHOX are available upon request.
Upstream qPCR-based copy number profiling. CNV analysis was performed as previously 
described with minor modifications (Supplementary Data S6)18. Three amplicons, one for each upstream 
CNE (CNE-5, CNE-3 and CNE-2), were designed and subjected to stringent in silico and in vitro val-
idations to guarantee their specificity and efficiency39. Next, qPCR reactions were carried out on the 
LightCycler 480 Instrument II (Roche Applied Science, Penzberg, Germany) and data-analysis was sub-
sequently performed with the commercially available qBasePlus software (Biogazelle NV, Zwijnaarde, 
Belgium)40. Two reference genes, ZNF80 and GPR15, were used for normalization of the relative quan-
tities and three positives controls with known copy number were used as a reference to calculate the 
copy numbers.
Array-based comparative genomic hybridization (arrayCGH). Genome-wide copy number 
profiling was performed on 180 K oligonucleotide arrays (Agilent Technologies, Santa Clara, CA). In 
addition, a custom high-resolution 8 × 60 K Agilent microarray was designed using the online design 
tool eArray, targeting a region of 693 kb around SHOX (chrX:247,599–940,876; UCSC, Human Genome 
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Browser, hg19). Hybridizations were performed according to manufacturer’s instructions with minor 
modifications. The results were subsequently visualized in arrayCGHbase41.
Chromosome conformation capture assays (4C-seq). The experimental chicken procedures have 
been performed following the protocols approved by the Ethical Committee for Animal Research from 
Consejo Superior de Investigaciones (CSIC) according to the European Union regulations. The 4C-seq 
assay was performed as previously reported33,42–44. HH28 chicken embryos were dissected and limbs 
were processed to obtain approximately 10 million isolated cells. Human U2OS cells were processed 
to obtain 4.5 million cells. Human and chicken samples were equally processed. Cells were lysed (lysis 
buffer: 10 mM Tris-HCl pH 8, 10 mM NaCl, 0.3% IGEPAL CA-630 (Sigma-Aldrich, St. Louis, MO), 
1X protease inhibitor cocktail (Roche Applied Science), the DNA digested with DpnII endonuclease 
(New England Biolabs, Ipswich, MA) and ligated with T4 DNA ligase (Promega). Subsequently, Csp6I 
endonuclease (Thermo Fisher Scientific, Waltham, MA) was used in a second round of digestion, and 
the DNA was ligated again. Specific primers were designed at the Shox promoter with Primer3 v. 0.4.045 
(Supplementary Data S7). Illumina adaptors were included in the primers sequence and 16 PCRs were 
performed with Expand Long Template PCR System (Roche Applied Science) and pooled together. This 
library was purified with a High Pure PCR Product Purification Kit (Roche Applied Science); its concen-
tration measured using the Quanti-iTTM PicoGreen dsDNA Assay Kit (Life technologies) and sent for 
deep sequencing. The 4C-seq data were analysed as previously described43. Briefly, chicken and human 
raw sequencing data were de-multiplexed and aligned using the Chicken May 2006 assembly (galGal3) 
and Human February 2009 (hg19) respectively, as the reference genome. Reads located in fragments 
flanked by two restriction sites of the same enzyme, or in fragments smaller than 40 bp were filtered out. 
Mapped reads were then converted to reads-per-first-enzyme-fragment-end units, and smoothed using 
a mean running window algorithm. Data was submitted to GEO under accession GSE65959.
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